New schizophrenia drug could ‘change the lives of millions of people’
The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...
technologynetworks7m
FDA Approves First Schizophrenia Treatment With a Novel Target in 70 Years
The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
kffhealthnews38m
Antipsychotic Drug Cobenfy Wins FDA Approval For Schizophrenia Treatment
The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...
Dow Jones Today: Stock Futures Little Changed Ahead of Key Inflation Data
Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...
Managed Healthcare Executive53m
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
FDA approves new kind of drug for schizophrenia
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
5 things to know before the stock market opens Friday
There's a newly approved drug for schizophrenia from Bristol Myers Squibb.
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...
bovnews1h
Bristol Myers Squibb (BMY): A New Era in Schizophrenia Treatment and Stock Market Performance
As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...